Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15999777 | 0.91 | NOTUM (0.42) | CES2NOTUMGPR35GAAMAPT | |
| SCHEMBL28960214 | 0.85 | NPSR1 (0.54) | CES2GAAMAPTP2RX1NPSR1 | |
| SCHEMBL14638979 | 0.84 | CES2 (0.47) | CES2MAPT | |
| SCHEMBL707474 | 0.83 | GPR35 (0.47) | CES2NOTUMGPR35GAANPSR1 | |
| SCHEMBL15229000 | 0.81 | CES2 (0.52) | CES2NOTUMGAAMAPTP2RX1 | |
| SCHEMBL2895507 | 0.80 | CES2 (0.53) | CES2NOTUMGPR35GAAP2RX1 | |
| SCHEMBL27153196 | 0.78 | CES2 (0.42) | CES2HDAC3HDAC6HDAC1HDAC2 | |
| SCHEMBL4597295 | 0.77 | KDM1A (0.47) | CES2 | |
| SCHEMBL5773805 | 0.76 | CES2 (0.53) | CES2NOTUMGPR35GAAMAPT | |
| SCHEMBL4020790 | 0.75 | CES2 (0.52) | CES2NOTUMGPR35GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1089710-B1 | INJECTABLE PHARMACEUTICAL FORMULATIONS OF PARTRICIN DERIVATIVES | PRO APARTS INVESTIMENTOS E CON (PT) | 2005-08-10 | — | — | EP | claimed |
| WO-2005053677-A1 | USE OF PARTRICIN DERIVATIVES FOR TREATING FUNGAL AND PROTOZOAL INFECTIONS | PRO APARTS-INVESTIMENTOS E CONSULTORIA LDA (PT) | 2005-06-16 | — | — | WO | claimed |
| EP-0489308-B1 | Partricin derivatives | PRODOTTI ANTIBIOTICI SPA (IT) | 1998-09-02 | — | — | EP | claimed |
| US-5298495-A | Partricin derivatives | SPA SOCIETA' PRODOTTI ANTIBIOTICI SPA (IT) | 1994-03-29 | — | — | US | claimed |
| JP-3188096-A | — | — | None | — | — | JP | disclosed |
| US-10093609-B2 | TAK1 kinase inhibitors, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170369417-A1 | TAK1 Kinase Inhibitors, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-28 | — | — | US | disclosed |
| US-9751825-B2 | TAK1 kinase inhibitors, compositions, and used related thereto | EMORY UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20140249199-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | HEALTH RESEARCH, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013012998-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | EMORY UNIVERSITY (US) | 2013-01-24 | — | — | WO | disclosed |
| US-6953792-B2 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| EP-1551832-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-0434943-B1 | Polyene macrolide derivatives | PRODOTTI ANTIBIOTICI SPA (IT) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995021819-A1 | ARALKOXY AND ARALKYLTHIO SUBSTITUTED AZACYCLIC COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995019344-A1 | GEM-DISUBSTITUTED AZACYCLIC TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-07-20 | — | — | WO | disclosed |
| US-5298495-A | Partricin derivatives | SPA SOCIETA' PRODOTTI ANTIBIOTICI SPA (IT) | 1994-03-29 | — | — | US | disclosed |
| US-5296597-A | Antibiotics | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.P.A. (IT) | 1994-03-22 | — | — | US | disclosed |
| EP-0489308-A1 | Partricin derivatives | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. (IT) | 1992-06-10 | — | — | EP | disclosed |
| JP-H03188096-A | POLYENE-MACROLIDE DERIVATIVE | SPA SOC PRODOTTI ANTIBIOTICI SPA | 1991-08-16 | — | — | JP | disclosed |
| EP-0434943-A1 | Polyene macrolide derivatives | S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a. (IT) | 1991-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093609-B2 | TAK1 kinase inhibitors, compositions, and uses related thereto | TAB1, MAP3K1, MAP3K6 | CES2 4396/4885NOTUM 3118/4885GPR35 4558/4885 |
| US-20140249199-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | TAB1, MAP3K1, MAP3K6 | CES2 4538/4885NOTUM 3184/4885GPR35 4470/4885 |
| US-20170369417-A1 | TAK1 Kinase Inhibitors, Compositions, and Uses Related Thereto | TAB1, MAP3K1, MAP3K6 | CES2 4396/4885NOTUM 3118/4885GPR35 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.